Causes and predisposing for the development of serological resistance after treatment of syphilitic infection

Syphilis is an infectious disease caused by pale treponema, transmitted mainly through sexual contact (STDs). The disease is characterized by lesions of the skin, mucous membranes, internal organs, nervous and musculoskeletal systems; in addition, it is characterized by a staged, recurrent and progressive course. Currently, there is an increase in the number of patients with serological resistance, which is characterized by persistent positive non-treponemal tests without a tendency to decrease antibody titers for 12 months after adequate therapy. Serological resistance leads to rapid disability of patients or their death. The aim of this research was to study the factors of seroresistance formation in patients with syphilis who have undergone a full course of specific therapy with various drugs in the Yakutsk Republic’s Dermatovenerological Dispensary. The study covered 57 patients with seroresistance in the period 2002–2024. Thus, the prevalence of seroresistance among patients with syphilis in the Sakha Republic (Yakutia) made 0.5 %. The average age was 41+12.9 years; by gender, women predominated with 57.1 %. As a primary diagnosis in patients with seroresistance, latent early syphilis with 66.7 % predominated. Serological resistance formed on average after 28 months. Primary treatment of patients with syphilis with reserve drugs from the group of the 3rd generation cephalosporins was received by 59.6 % of the patients, and with penicillin drugs – 40.4 %. Almost the same data were obtained in the treatment of the patients with serological resistance, which amounted to 60 % and 40 %, respectively. In the structure of concomitant diseases, viral hepatitis was noted in 7 %, STIs – in 3.5 %, HIV – in 1.8 % of the patients.

1. World Health Organization. Syphilis. May 29, 2025 (in Russian). DOI: https://www.who.int/ru/news-room/fact-sheets/detail/syphilis

2. Kotova E.G., Kobyakova O.S., Kubanov A.A., et al. Resources and activities of medical organizations specializing in dermatovenereology. Incidence of sexually transmitted infections, contagious skin diseases, and skin diseases in 2021. Moscow: Central Research Institute of Skin and Venereal Diseases of the Ministry of Health of the Russian Federation, 2022:213 (in Russian). DOI: https://www.elibrary.ru/download/elibrary_50154224_12547128.pdf

3. Bokhonovich D.V. Clinical and serological monitoring as a criterion for the effectiveness of syphilis treatment. Candidate’s Dissertation (Medicine). 2019:156 (in Russian). DOI: https://www.sechenov.ru/upload/medialibrary/732/dissertatsiya-itog.pdf

4. Global health sector strategy on sexually transmitted infections, 2016–2021. WHO; 2016 (in Russian). DOI: https://iris.who.int/server/api/core/bitstreams/48c1f835-f478-4a1b-8bb0-69ffb78de505/content

5. Sharipova A.Sh., Petunova Ya.G., Serological resistance after treatment of acquired syphilis: predisposing factors. Graduation qualification work. 2021:53 (in Russian). DOI: https://api.dspace.spbu.ru/server/api/core/bitstreams/9875f961-500e-43e6-abdf-a6a09b1c0c72/content

6. Kubanov A.A., Bogdanova E.V. Results of the activities of medical organizations providing medical care in the profile of “dermatovenereology” in 2019-2021 in the Russian Federation. Bulletin of Dermatology and Venereology. 2022;98(5):18–33 (in Russian). DOI: https://www.elibrary.ru/download/elibrary_49891133_26446206.pdf

7. Kubanova A.A., Melekhina L.E., Kubanov A.A. The main objectives of the development of dermatovenereological care to the population of the Russian Federation for the period up to 2024. Results of the activities of medical organizations in providing dermatovenereological care to the population of the Russian Federation in 2017. Bulletin of Dermatology and Venereology. 2018;94 (5):9–25 (in Russian). DOI: https://www.elibrary.ru/download/elibrary_36878323_99935128.pdf

8. Obraztsova O.A., et al. Prevalence of the A2058G mutation in the 23S rRNA gene in the Russian population of T. pallidum. Clinical Microbiology and Antimicrobial Chemotherapy. 2022;24(4):369–374 (in Russian). DOI: https://www.researchgate.net/publication/369471720_Prevalence_of_the_A2058G_mutation_in_23S_rRNA_gene_which_determines_Treponema_pallidum_macrolide_resistance_in_Russian_population

9. Polyakova N.V., Kungurov N.V., Zilberberg N.V., et al. Syphilis in children and adolescents: epidemiological and socio-dermographic aspects of morbidity. Modern problems of science and education. 2015 (in Russian). DOI: https://science-education.ru/ru/article/view?id=22707

10. Prokhorenkov V.I., Ostrovsky A.E. Seroresistance: modern aspects of the problem and prospects (literature review). Siberian Medical Review. 2002;3 (in Russian). DOI: https://cyberleninka.ru/article/n/serorezistentnostsovremennye-aspekty-problemy-i-perspektivy-obzor-literatury/viewer

11. Sokolovsky E.V., et al. Dermatovenereology. St. Petersburg: Spetsit, 2017:517–633 (in Russian).

12. Fedotov V.P., Dyudyun A.D., Gorbuntsov V.V., et al. Problems of seroresistance in patients with syphilis and new approaches to its therapy. DVKS. 2011 (in Russian). DOI: https://cyberleninka.ru/article/n/problemyserorezistentnosti-u-bolnyh-sifilisom-i-novye-podhody-v-eyo-terapii/viewer

13. Katunin G.L., Plakhova K.I., Abduduev N.K., et al. Ceftriaxone in the treatment of patients with syphilis. Bulletin of Dermatology and Venereology. 2021;97:2;23–31 (in Russian). DOI: https://www.elibrary.ru/download/elibrary_45728941_43918588.pdf

14. Suggested citation: European Centre for Disease Prevention and Control. Syphilis. In: ECDC. Annual epidemiological report for 2019. Stockholm: ECDC; 2022. DOI: https://www.ecdc.europa.eu/sites/default/files/documents/syphilis-annual-epidemiological-report-2019.pdf

15.